Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

4Front Ventures

CNSX:FFNT
Snowflake Description

Imperfect balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FFNT
CNSX
CA$274M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The last earnings update was 85 days ago. More info.


Add to Portfolio Compare Print
  • 4Front Ventures has significant price volatility in the past 3 months.
FFNT Share Price and Events
7 Day Returns
-10.5%
CNSX:FFNT
-1.8%
CA Pharmaceuticals
0.2%
CA Market
1 Year Returns
-
CNSX:FFNT
-59.2%
CA Pharmaceuticals
4.6%
CA Market
FFNT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
4Front Ventures (FFNT) -10.5% -23.9% -19% - - -
CA Pharmaceuticals -1.8% -13.9% -10.4% -59.2% 14.7% 327.1%
CA Market 0.2% 0.5% 4% 4.6% 7.2% 14.2%
1 Year Return vs Industry and Market
  • No trading data on FFNT.
  • No trading data on FFNT.
Price Volatility
Industry
5yr Volatility vs Market

FFNT Value

 Is 4Front Ventures undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for 4Front Ventures. This is due to cash flow or dividend data being unavailable. The share price is CA$0.51.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for 4Front Ventures's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are 4Front Ventures's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:FFNT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.03
CNSX:FFNT Share Price ** CNSX (2020-02-21) in CAD CA$0.51
CNSX:FFNT Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.757 $0.39
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 16.05x
Canada Market PE Ratio Median Figure of 510 Publicly-Listed Companies 16.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of 4Front Ventures.

CNSX:FFNT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:FFNT Share Price ÷ EPS (both in USD)

= 0.39 ÷ -0.03

-12.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 4Front Ventures is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • 4Front Ventures is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does 4Front Ventures's expected growth come at a high price?
Raw Data
CNSX:FFNT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 1.55x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 1.13x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for 4Front Ventures, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on 4Front Ventures's assets?
Raw Data
CNSX:FFNT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $0.45
CNSX:FFNT Share Price * CNSX (2020-02-21) in CAD CA$0.51
CNSX:FFNT Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.757 $0.39
Canada Pharmaceuticals Industry PB Ratio Median Figure of 154 Publicly-Listed Pharmaceuticals Companies 1.5x
Canada Market PB Ratio Median Figure of 2,342 Publicly-Listed Companies 1.4x
CNSX:FFNT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:FFNT Share Price ÷ Book Value per Share (both in USD)

= 0.39 ÷ 0.45

0.86x

* Primary Listing of 4Front Ventures.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 4Front Ventures is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess 4Front Ventures's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. 4Front Ventures has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

FFNT Future Performance

 How is 4Front Ventures expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
73.9%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is 4Front Ventures expected to grow at an attractive rate?
  • Unable to compare 4Front Ventures's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare 4Front Ventures's earnings growth to the Canada market average as no estimate data is available.
  • 4Front Ventures's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:FFNT Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:FFNT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 73.9%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 69.1%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 40.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 10.9%
Canada Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:FFNT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:FFNT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 227 27 3
2020-12-31 144 -2 3
2020-02-22
2019-12-31 67 -23 3
CNSX:FFNT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 18 -20 -17
2018-12-31 4 -11 -7
2018-09-30 1 -8 -9
2017-12-31 1 -4 -4
2016-12-31 2 -8 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if 4Front Ventures is high growth as no earnings estimate data is available.
  • 4Front Ventures's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:FFNT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from 4Front Ventures Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:FFNT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2020-02-22
2019-12-31
CNSX:FFNT Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.03
2018-12-31
2018-09-30
2017-12-31
2016-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if 4Front Ventures will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess 4Front Ventures's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
4Front Ventures has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

FFNT Past Performance

  How has 4Front Ventures performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare 4Front Ventures's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • 4Front Ventures does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare 4Front Ventures's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare 4Front Ventures's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
4Front Ventures's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from 4Front Ventures Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:FFNT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 18.09 -16.70 25.24
2018-12-31 3.66 -7.47 12.69
2018-09-30 1.18 -9.26 8.77
2017-12-31 0.72 -3.59 4.34
2016-12-31 2.01 -4.50 14.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if 4Front Ventures has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if 4Front Ventures has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if 4Front Ventures improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess 4Front Ventures's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
4Front Ventures has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

FFNT Health

 How is 4Front Ventures's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up 4Front Ventures's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • 4Front Ventures is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • 4Front Ventures's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of 4Front Ventures's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from 4Front Ventures Company Filings, last reported 4 months ago.

CNSX:FFNT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 239.13 75.54 12.53
2018-12-31 52.67 9.20 1.26
2018-09-30 18.71 3.49 2.35
2017-12-31 -0.56 13.23 3.61
2016-12-31 1.97 3.26 2.06
  • 4Front Ventures's level of debt (31.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if 4Front Ventures's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • 4Front Ventures has less than a year of cash runway based on current free cash flow.
  • 4Front Ventures has less than a year of cash runway if free cash flow continues to grow at historical rates of 49.9% each year.
X
Financial health checks
We assess 4Front Ventures's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. 4Front Ventures has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

FFNT Dividends

 What is 4Front Ventures's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from 4Front Ventures dividends.
If you bought CA$2,000 of 4Front Ventures shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate 4Front Ventures's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate 4Front Ventures's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:FFNT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 335 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:FFNT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-02-22
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as 4Front Ventures has not reported any payouts.
  • Unable to verify if 4Front Ventures's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of 4Front Ventures's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as 4Front Ventures has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess 4Front Ventures's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can 4Front Ventures afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. 4Front Ventures has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

FFNT Management

 What is the CEO of 4Front Ventures's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Josh Rosen
CEO Bio

Mr. Joshua N. Rosen, also known as Josh, is CEO & Director at 4Front Ventures Corp. since July 2019. Mr. Rosen co-founded 4Front Ventures, Inc. in 2014 and serves as its Chief Executive Officer. Mr. Rosen serves as Vice Chairman and Acting Chief Financial officer at Southwest Solar Technologies Incorporated. Mr. Rosen served as a Research Analyst at Crédit Suisse AG, Research Division and was a Research Analyst at RBS Research. Mr. Rosen was a Director-level research analyst at Credit Suisse in the Equity Research Department, lending his rigorous analytic and decision making background and capital markets experience to the Southwest Solar executive team. After 13 years as an equity analyst and portfolio manager evaluating and investing in publicly traded companies, he wanted to have a more meaningful impact on companies. He joined a solar company in Phoenix in 2008, as Chief Financial Officer before assuming the role of President and Vice Chairman. He co-founded 4Front Advisors in 2011 to provide consultative support and manage a venture capital fund for the family office for John Sperling, a long-time drug reform advocate. The first investment in the venture capital fund was the acquisition of intellectual property from CannBe and the subsequent formation of 4Front Advisors in 2011. His early career included being among the youngest Vice President in Credit Suisse’s history. He earned a B.A. degree in economics and philosophy from Beloit College in 1995.

CEO Compensation
  • Insufficient data for Josh to compare compensation growth.
  • Insufficient data for Josh to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure of the 4Front Ventures management team in years:

0.9
Average Tenure
  • The average tenure for the 4Front Ventures management team is less than 2 years, this suggests a new team.
Management Team

Josh Rosen

TITLE
CEO & Director

Kris Krane

TITLE
President

Brad Kotansky

TITLE
Chief Financial Officer

Trevor Pratte

TITLE
Secretary and Co-COO
AGE
39

Andrew Thut

TITLE
Chief Investment Officer

Clay Crolius

TITLE
Principal Accounting Officer & Controller
TENURE
0.4 yrs

Alicia Mandel

TITLE
Chief Human Performance Officer
TENURE
0.3 yrs

Leo Gontmakher

TITLE
President of Brightleaf Development (Production) & Director
AGE
32

David Nathan

TITLE
Chief Medical Advisor
TENURE
1.3 yrs

Leah Heise

TITLE
Chief Experience Officer
TENURE
1.8 yrs
Board of Directors

Eric Rey

TITLE
Chairman of the Board
AGE
63

Josh Rosen

TITLE
CEO & Director

Leo Gontmakher

TITLE
President of Brightleaf Development (Production) & Director
AGE
32

Betty Aldworth

TITLE
Director
TENURE
0.4 yrs

Kathi Lentzsch

TITLE
Director
TENURE
0.4 yrs

David Daily

TITLE
Director
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by 4Front Ventures individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
11. Dec 19 Buy Eric Rey Individual 11. Dec 19 11. Dec 19 20,000 CA$0.57 CA$11,477
10. Dec 19 Buy Kea Capital Llc Company 05. Dec 19 09. Dec 19 234,000 CA$0.64 CA$133,669
09. Dec 19 Buy Kea Capital Llc Company 04. Dec 19 04. Dec 19 5,000 CA$0.58 CA$2,843
06. Dec 19 Buy Brad Kotansky Individual 05. Dec 19 05. Dec 19 10,000 CA$0.50 CA$5,021
05. Dec 19 Buy David Daily Individual 04. Dec 19 04. Dec 19 22,000 CA$0.57 CA$12,477
05. Dec 19 Buy Brad Kotansky Individual 03. Dec 19 04. Dec 19 34,500 CA$0.56 CA$18,776
26. Sep 19 Buy Leonid Gontmakher Individual 26. Sep 19 26. Sep 19 100,000 CA$0.79 CA$78,810
25. Sep 19 Buy Leonid Gontmakher Individual 25. Sep 19 25. Sep 19 43,200 CA$0.75 CA$32,568
24. Sep 19 Buy Leonid Gontmakher Individual 24. Sep 19 24. Sep 19 26,000 CA$0.78 CA$20,313
19. Sep 19 Buy Leonid Gontmakher Individual 18. Sep 19 18. Sep 19 95,000 CA$0.70 CA$65,938
16. Sep 19 Buy Leonid Gontmakher Individual 12. Sep 19 13. Sep 19 85,000 CA$0.77 CA$64,308
13. Sep 19 Buy Brad Kotansky Individual 10. Sep 19 12. Sep 19 45,500 CA$0.79 CA$34,640
06. Sep 19 Buy Leonid Gontmakher Individual 06. Sep 19 06. Sep 19 15,000 CA$0.87 CA$12,980
06. Sep 19 Buy Brad Kotansky Individual 04. Sep 19 04. Sep 19 30,000 CA$0.82 CA$23,901
06. Sep 19 Buy Andrew Thut Individual 04. Sep 19 05. Sep 19 145,000 CA$0.87 CA$115,426
X
Management checks
We assess 4Front Ventures's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. 4Front Ventures has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

FFNT News

Simply Wall St News

Could 4Front Ventures Corp.'s (CNSX:FFNT) Investor Composition Influence The Stock Price?

Check out our latest analysis for 4Front Ventures CNSX:FFNT Ownership Summary, August 9th 2019 What Does The Institutional Ownership Tell Us About 4Front Ventures? … Less than 5% of 4Front Ventures is held by institutional investors. … Insider Ownership Of 4Front Ventures The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

FFNT Company Info

Description

4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. It operates through three segments: Retail, Production, and Real Estate. The company produces cannabis and CBD. It also owns and operates two dispensaries in Massachusetts; three in Maryland; and one each in Illinois, Michigan, Pennsylvania, Arizona, and Arkansas. In addition, the company sells supplies to cannabis producers, as well as non-TCH products; imports equipment and supplies for resale; and leases real estate properties. Further, it provides consulting services in the areas of cannabis sector, including cultivation, production, and distribution and retail. The company was founded in 2011 and is headquartered in Phoenix, Arizona.

Details
Name: 4Front Ventures Corp.
FFNT
Exchange: CNSX
Founded: 2011
CA$273,633,166
536,535,620
Website: http://4frontventures.com
Address: 4Front Ventures Corp.
5060 North 40th Street,
Suite 120,
Phoenix,
Arizona, 85018,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX FFNT Class A Subordinate Voting Shares Canadian National Stock Exchange CA CAD 20. Mar 2018
OTCPK FFNT.F Class A Subordinate Voting Shares Pink Sheets LLC US USD 20. Mar 2018
Number of employees
Current staff
Staff numbers
300
4Front Ventures employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/22 03:20
End of day share price update: 2020/02/21 00:00
Last estimates confirmation: 2020/01/10
Last earnings filing: 2019/11/29
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.